Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**α-Amanitin** is a highly toxic bicyclic octapeptide toxin primarily found in *Amanita phalloides* (death cap mushroom) and other species like *Galerina marginata*. It potently and irreversibly inhibits **eukaryotic RNA polymerase II** by binding to its bridging helix, preventing RNA translocation and transcription elongation, which blocks mRNA synthesis and leads to rapid hepatocyte cytolysis. With an oral LD50 of ~0.1 mg/kg in humans, it causes delayed but fatal liver failure; emerging applications include use as a payload in **antibody-drug conjugates (ADCs)** for therapy-resistant cancers due to its activity in non-dividing, multidrug-resistant cells at picomolar concentrations and low aggregation tendency.[1][2][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on α-amanitin.